HLS:CC News and Press, HLS Therapeutics Inc. From 05/03/23

HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call Canada NewsWire TORONTO , May 3, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2023 financial results on Thursday, M...

HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO , April 21, 2023 /CNW/ - HLS Therapeutics Inc. ...

HLS Therapeutics Announces CEO Transition Canada NewsWire •     Craig Millian to replace retiring CEO, Gilbert Godin , on May 1, 2023 TORONTO , April 17, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company...

HLS Therapeutics Announces Q4 and Fiscal 2022 Financial Results Canada NewsWire TORONTO , March 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular...

HLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , March 2, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 and Fiscal 2022 financial results on T...

Healthcare stocks aren’t attractive to investors in 2022. The selloff is more severe than information technology, given the sector’s year-to-date loss of nearly 51%. Moreover, underperforming cannabis stocks like Canopy Growth , Tilray , and Cronos Group are among th...

HLS Therapeutics Announces Board Appointment Canada NewsWire TORONTO , Nov. 29, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces ...

HLS Therapeutics to Present at the Stifel Healthcare Conference Canada NewsWire TORONTO , Nov. 14, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular market...

HLS Therapeutics Announces Q3 Fiscal 2022 Financial Results and Renewal of Normal Course Issuer Bid Canada NewsWire Q3 2022 revenue of $15.7 million , Adjusted EBITDA of $6.0 million and cash from operations of $4.2 million . Total Vascepa prescri...

HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at the American Heart Association Canada NewsWire Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular Risk Reduction Benefits of Eicosapentaen...